



Newsletter from Emotra AB (publ)

Göteborg, September 8, 2016

## A short update – Emotra is off to Oviedo for some meetings

**During the next few days, on September 8–11, Emotra will be participating in the 16th European Symposium on Suicide and Suicidal Behaviour, ESSSB, in Oviedo, Spain. EDOR® will be presented in different contexts during the conference and a special workshop about the method will also be held. In addition to this, Emotra and Professor Marco Sarchiapone, the Company's scientific advisor, will be arranging two separate meetings with leading European, American and Asian clinics.**

On top of a number of smaller presentations and workshops about EDOR® at this conference, Emotra will, with Marco Sarchiapone's assistance, arrange two separate meetings at the ESSSB conference. On September 9, a meeting focusing on suicide among young people will be held. According to our plans, the European Psychiatric Association's Suicide Section, EPASS, and Emotra will be initiating a study, EUDOR-Y, next year to document the testing of young people between 12 and 20 years of age with EDOR®. Suicide among young people is an enormous problem in the EU, and the trend is pointing steadily upward. Everyone in the profession agrees that we must do everything possible to reverse this trend. Luckily, the number of clinics who have registered their interest in participating in this study has also increased steadily. A total of 26 clinics will be attending this planning meeting in Oviedo.

*"We are very pleased to see that the interest in participating in our EDOR® studies is so strong. Most importantly, this is a reflection of how difficult it is for the psychiatric profession to determine which patients are at risk of attempting suicide. However, it is also an indication of the positive attitude and faith in our method that the clinics participating in our ongoing study on adults, EUDOR-A, have," says Claes Holmberg, Emotra's CEO.*

Emotra will be applying for funding from the European Commission's Horizon 2020 program to finance its youth study. We expect to receive their grant decision in January, 2017. If we are granted funding, we should be able to start our study in spring 2017. If our application is rejected, we will rework it and resubmit it to the EC later in 2017.

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden

Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)



On September 10, "World Suicide Prevention Day", we will be holding an important meeting with the clinics involved in our EUDOR-A study to present and discuss the study's baseline material. This meeting will also decide how we will wind up our study in March 2017. It is very important that all reporting is sent to Rome promptly, since we plan on presenting the study results at the important EPA Psychiatry Congress on April 1–4, 2017 in Florence, Italy.

In addition to these two meetings, Emotra will be hosting a dinner for all of the EUDOR-A clinics and the prospective EUDOR-Y clinics. Our Publication Committee, PC, will also be meeting in connection with the Oviedo conference. The PC meeting will discuss the publication of a scientific article about our baseline material, as well as future publication and disclosure of our follow-up results. After the Oviedo meeting, Emotra will be reporting on the results of these different activities.

*"With every new international meeting, our method garners increasing attention and interest. This is a very important indicator of the amount of support we should expect from the profession once we launch our product", states Lars-Håkan Thorell, the method's inventor and Emotra's head of research. "However, we must also remember that any future support is ultimately dependent on the outcome of our EUDOR-A study. The results must show that EDOR® is reliable and for the vast majority of patients is able to identify those patients who are at risk of attempting suicide. Naturally, we are prepared for the possibility that our study will also reveal smaller patient groups that display such complex diagnostic circumstances, or whose medical treatment situation is so complex, that testing with EDOR® is not yet feasible," the head of research continues.*

Later this autumn, the inventor of EDOR® Lars-Håkan Thorell, will be presenting his research results as one of the invited keynote speakers at a large and important international conference on bipolar disorders in Chicago.

Emotra's CEO, Claes Holmberg, will be presenting Emotra at MTI in London, England on September 20–21. He will also be holding a presentation of the company at the Swedish Shareholders' Association's meeting in Falköping on October 17 and at Stora Aktiedagen on November 14 in Göteborg.

**For further information, please contact:** Claes Holmberg, CEO. Telephone: +46 708 25 45 47, E-mail: [claes@emotra.se](mailto:claes@emotra.se)

---

**Emotra AB (publ)** is a medical technology company that carries out research, development, clinical studies and marketing in the area of suicide prevention. The Company's method, EDOR®, is a proprietary, objective and quantitative diagnostic, psychophysiological test for detecting hyporeactivity in patients suffering from depression. During the test, the patient listens to a series of audio signals. The patient's response, in the form of very small changes in dermal electric conductivity, is measured and analysed. This extremely sensitive and specific test of suicidal risk has been developed as the result of research.

Emotra AB (publ), Göteborgsvägen 74, SE-433 63 Sävedalen, Sweden  
Tel: +46 708 25 45 47, [www.emotra.se](http://www.emotra.se)